These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 28604554)

  • 41. Ipilimumab Induced Hypophysitis: MRI Findings in a Series of 3 Cases.
    Wadhwa V
    J Ark Med Soc; 2017 May; 113(11):270-272. PubMed ID: 30351740
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ipilimumab-associated cholestatic hepatitis: a case report and literature review.
    Yildirim S; Deniz K; Doğan E; Başkol M; Gürsoy Ş; Özkan M
    Melanoma Res; 2017 Aug; 27(4):380-382. PubMed ID: 28489679
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report.
    Yonezaki K; Kobayashi T; Imachi H; Yoshimoto T; Kikuchi F; Fukunaga K; Sato S; Ibata T; Yamaji N; Lyu J; Dong T; Murao K
    J Med Case Rep; 2018 Jun; 12(1):171. PubMed ID: 29914537
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ipilimumab-induced toxicities and the gastroenterologist.
    Cheng R; Cooper A; Kench J; Watson G; Bye W; McNeil C; Shackel N
    J Gastroenterol Hepatol; 2015 Apr; 30(4):657-66. PubMed ID: 25641691
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bilateral Paraneoplastic Orbital Myositis Associated With Malignant Melanoma and Multiple Myeloma.
    Hunt SV; Garrott HM; Williams ME; Ford RL
    Ophthalmic Plast Reconstr Surg; 2022 May-Jun 01; 38(3):e72-e75. PubMed ID: 34873125
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ipilimumab-induced Guillain-Barré Syndrome Presenting as Dysautonomia: An Unusual Presentation of a Rare Complication of Immunotherapy.
    Kelly Wu W; Broman KK; Brownie ER; Kauffmann RM
    J Immunother; 2017 Jun; 40(5):196-199. PubMed ID: 28452849
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
    Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
    J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH.
    Siddiqui MS; Lai ZM; Spain L; Greener V; Turajlic S; Larkin J; Morganstein DL
    J Endocrinol Invest; 2021 Jan; 44(1):195-203. PubMed ID: 32449093
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy.
    Balatoni T; Mohos A; Papp E; Sebestyén T; Liszkay G; Oláh J; Varga A; Lengyel Z; Emri G; Gaudi I; Ladányi A
    Cancer Immunol Immunother; 2018 Jan; 67(1):141-151. PubMed ID: 28988380
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A case of aseptic meningitis without neck rigidity occurring in a metastatic melanoma patient treated with ipilimumab.
    Oishi K; Nakao M; Maeda S; Matsushita T; Ikeda T; Yamada T; Takehara K; Hamaguchi Y
    Eur J Dermatol; 2017 Apr; 27(2):193-194. PubMed ID: 28007669
    [No Abstract]   [Full Text] [Related]  

  • 51. Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma.
    Failing JJ; Finnes HD; Kottschade LA; Allred JB; Markovic SN
    Melanoma Res; 2016 Dec; 26(6):609-615. PubMed ID: 27603551
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acute liver graft rejection after ipilimumab therapy.
    Dueland S; Guren TK; Boberg KM; Reims HM; Grzyb K; Aamdal S; Julsrud L; Line PD
    Ann Oncol; 2017 Oct; 28(10):2619-2620. PubMed ID: 28961840
    [No Abstract]   [Full Text] [Related]  

  • 53. Remote-onset alopecia areata attributed to ipilimumab.
    Pearson DR; Lewis K; Alkousakis T
    Cutis; 2019 Dec; 104(6):E25-E27. PubMed ID: 31939941
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Ipilimumab induced colitis].
    Thielsen P; Svane IM
    Ugeskr Laeger; 2015 Nov; 177(46):V66773. PubMed ID: 26573945
    [No Abstract]   [Full Text] [Related]  

  • 55. Ipilimumab-related hypophysitis may precede severe CNS immune attack.
    Köessler T; Olivier T; Fertani S; Marinari E; Dutoit V; Dietrich PY
    Ann Oncol; 2016 Oct; 27(10):1975-6. PubMed ID: 27358386
    [No Abstract]   [Full Text] [Related]  

  • 56. Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases.
    Garcia CA; El-Ali A; Rath TJ; Contis LC; Gorantla V; Drappatz J; Davar D
    J Immunother Cancer; 2018 Aug; 6(1):83. PubMed ID: 30170622
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Toxic Injury to the Gastrointestinal Tract After Ipilimumab Therapy for Advanced Melanoma.
    Shepard B; Trower C; Hendrickson S
    J Am Osteopath Assoc; 2018 Jan; 118(1):40-44. PubMed ID: 29309091
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ipilimumab-related orbitopathy: a case report.
    Jebaraj AP; Etheridge TJ; Winegar BA; Marx DP
    Orbit; 2024 Feb; 43(1):100-104. PubMed ID: 35581713
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acute autoimmune myocarditis and hepatitis due to ipilimumab monotherapy for malignant melanoma.
    Samara Y; Yu CL; Dasanu CA
    J Oncol Pharm Pract; 2019 Jun; 25(4):966-968. PubMed ID: 29444608
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Infliximab for severe colitis associated with nivolumab followed by ipilimumab.
    Fukumoto T; Fujiwara S; Tajima S; Tamesada Y; Sakaguchi M; Oka M; Nishigori C
    J Dermatol; 2018 Jan; 45(1):e1-e2. PubMed ID: 28891241
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.